Pharmacokinetics, Safety Profile, and Tolerability of MN-08 Tablets after Single and Multiple Ascending Doses in Healthy Chinese Volunteers Publication Pharmacokinetics, Safety Profile, and Tolerability of MN-08 Tablets after Single and Multiple Ascending Doses in Healthy Chinese Volunteers Find out how Phase I study shows dose-related MN-08 exposure, 21–32 h half-life, and good…CertaraFebruary 25, 2026
Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access Webinar Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access Danielle PillsburyFebruary 23, 2026
Start right, finish strong: Antibody-drug conjugate (ADC) studies for success On-Demand Webinar Start right, finish strong: Antibody-drug conjugate (ADC) studies for success Learn how to build regulatory-ready first-in-human (FIH) dose strategies for antibody-drug conjugates (ADCs). Discover how…CertaraFebruary 23, 2026
FAQs: The ICH M15 guideline and what it means for model-informed drug development Blog FAQs: The ICH M15 guideline and what it means for model-informed drug development Learn what the ICH M15 guideline means for Model-Informed Drug Development, regulatory credibility, harmonization, and…CertaraFebruary 18, 2026
Guided by Evidence: Implementing the ICH M15 Guideline for Model-Informed Drug Development (MIDD) Guide Guided by Evidence: Implementing the ICH M15 Guideline for Model-Informed Drug Development (MIDD) Prepare for ICH M15 guideline: Learn how to assess model credibility, align terminology, and strengthen…CertaraFebruary 13, 2026
Pediatric drug development: From “wild west” to model-informed confidence Blog Pediatric drug development: From “wild west” to model-informed confidence Model-informed drug development and precision dosing are transforming pediatric programs, from regulatory planning to Bayesian…CertaraFebruary 11, 2026
Why Many Global Drugs Never Reach Japan Press Coverage Why Many Global Drugs Never Reach Japan Despite faster reviews, many global drugs never reach Japan. Learn how early development decisions, trial…CertaraFebruary 5, 2026
Pharmacokinetic and toxicological evaluation of AB-CHMINACA in rodents: A comprehensive study Publication Pharmacokinetic and toxicological evaluation of AB-CHMINACA in rodents: A comprehensive study Explore how rodent study reveals 14 h half-life, key metabolites, and dose-dependent toxicity of AB-CHMINACA…CertaraFebruary 5, 2026
Trial designs: Non-inferiority vs. superiority vs. equivalence BlogKnowledge Base Trial designs: Non-inferiority vs. superiority vs. equivalence Understand superiority, non-inferiority, and equivalence trials, how their hypotheses differ, and how trial design impacts…Matt Zierhut, PhD MBAFebruary 3, 2026
Phoenix Roadshow 2026 – Florence Live Events Phoenix Roadshow 2026 – Florence CertaraFebruary 2, 2026